Myelotoxicity from chemotherapy.
Myelosuppression continues to be a major dose-limiting toxicity for most chemotherapy regimens. While the development of growth factors has changed the approach to myelosuppression, costs remain high and can be measured both in terms of quality of life (QOL) and economic outcomes. Growing data suggest that there may also be effects on response and survival in some tumors. This review will highlight the incidence, effect, and treatment/prevention of myelosuppression and briefly discuss the questions that remain.
Department of Hematology-Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Davey
D
Daniel
Jeffrey
J
Crawford
D000368:Aged; D000740:Anemia / Q000139:chemically induced* / Q000453:epidemiology; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001853:Bone Marrow / Q000187:drug effects*; D002986:Clinical Trials as Topic; D006801:Humans; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D009503:Neutropenia / Q000139:chemically induced* / Q000453:epidemiology; D011788:Quality of Life; D012307:Risk Factors; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000453:epidemiology
D000970:Antineoplastic Agents